Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ACRV Acrivon Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ACRV
Price (delayed)
$1.3
Market cap
$40.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.21
Enterprise value
$4.92M
We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our
Highlights
The EPS has grown by 24% YoY and by 7% from the previous quarter
Acrivon Therapeutics's debt has decreased by 21% YoY and by 3.6% QoQ
ACRV's equity is up by 49% YoY but it is down by 9% QoQ
ACRV's quick ratio is down by 9% YoY but it is up by 6% from the previous quarter
ACRV's net income is down by 31% year-on-year and by 4% since the previous quarter
Key stats
What are the main financial stats of ACRV
Market
Valuations
Earnings
Shares outstanding
31.36M
Market cap
$40.76M
Enterprise value
$4.92M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$93.19M
Net income
-$83.75M
EBIT
-$83.75M
EBITDA
-$81.7M
Free cash flow
-$70.13M
Per share
Balance sheet
Liquidity
EPS
-$2.21
EPS diluted
-$2.21
Free cash flow per share
-$1.83
Book value per share
$5.12
Revenue per share
$0
TBVPS
$4.6
Total assets
$176.35M
Total liabilities
$15.96M
Debt
$3.51M
Equity
$160.39M
Working capital
$137.78M
Debt to equity
0.02
Current ratio
11.17
Quick ratio
11.06
Net debt/EBITDA
0.44
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.9%
Return on equity
-44.7%
Return on invested capital
-55.2%
Return on capital employed
-51.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACRV stock price
How has the Acrivon Therapeutics stock price performed over time
Intraday
4.84%
1 week
4.84%
1 month
11.11%
1 year
-78.55%
YTD
-78.41%
QTD
-35.96%
Financial performance
How have Acrivon Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$93.19M
Net income
-$83.75M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 32% year-on-year and by 4.5% since the previous quarter
ACRV's net income is down by 31% year-on-year and by 4% since the previous quarter
Price vs fundamentals
How does ACRV's price correlate with its fundamentals
Growth
What is Acrivon Therapeutics's growth rate over time
Valuation
What is Acrivon Therapeutics stock price valuation
P/E
N/A
P/B
0.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 24% YoY and by 7% from the previous quarter
The P/B is 70% below the last 4 quarters average of 0.8
ACRV's equity is up by 49% YoY but it is down by 9% QoQ
Efficiency
How efficient is Acrivon Therapeutics business performance
The ROIC has grown by 10% YoY and by 2.1% from the previous quarter
Acrivon Therapeutics's return on equity has increased by 10% YoY and by 3.2% QoQ
The ROA has grown by 9% YoY and by 3.3% from the previous quarter
Dividends
What is ACRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACRV.
Financial health
How did Acrivon Therapeutics financials performed over time
The total assets is up by 46% year-on-year but it is down by 10% since the previous quarter
ACRV's total liabilities is up by 27% year-on-year but it is down by 19% since the previous quarter
Acrivon Therapeutics's debt is 98% lower than its equity
The debt to equity has dropped by 50% year-on-year
ACRV's equity is up by 49% YoY but it is down by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.